HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults

 

• New data show rising burden of most cardiovascular risk factors among young adults aged 20 to 44 in the U.S.
• Findings are “extremely concerning” as expert notes “we’re witnessing a smoldering public health crisis”
• HeartBeam has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere

A recent study shows that risk factors for cardiovascular (“CV”) disease are rising among young adults (https://ibn.fm/jvjFN). Studies like this that provide critical information regarding CV disease highlight the ongoing urgency of HeartBeam’s efforts. HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere.

“New data show a high and rising burden of most cardiovascular risk factors among young adults aged 20 to 44 years in the United States,” states a Medscape article, reporting on study findings presented at the March 5 annual meeting of the American College of Cardiology (“ACC”). “In this age group, over the past 10 years, there has been an increase in the prevalence of diabetes and obesity, no improvement in the prevalence of hypertension, and a decrease in the prevalence of hyperlipidemia.

“Yet medical treatment rates for CV risk factors are ‘surprisingly’ low among young adults,” study investigator Rishi Wadhera, MD, with Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, told theheart.org / Medscape Cardiology.

In the article, Wadhera noted that the findings are “extremely concerning.” He stated that “we’re witnessing a smoldering public health crisis. The onset of these risk factors earlier in life is associated with a higher lifetime risk of heart disease and potentially life threatening.”

The cross-sectional study comprised 12,294 U.S. participants aged 20 to 44 who participated in National Health and Nutrition Examination Survey (“NHANES”) cycles for 2009–2010 and 2017–March 2020. The mean age of group participants was 32, and 51% of participants were women.

The article reported that, “overall, the prevalence of hypertension was 9.3% in 2009–2010 and increased to 11.5% in 2017–2020. The prevalence of diabetes rose from 3.0% to 4.1%, and the prevalence of obesity rose from 32.7% to 40.9%. The prevalence of hyperlipidemia decreased from 40.5% to 36.1%.

“Equally concerning, said Wadhera, only about 55% of young adults with hypertension were receiving antihypertensive medication, and just 1 in 2 young adults with diabetes were receiving treatment,” the article continued. “Wadhera said, ‘We need to double down on efforts to screen for and treat cardiovascular risk factors like high blood pressure and diabetes in young adults. We need to intensify clinical and public health interventions focused on primordial and primary prevention in young adults now so that we can avoid a tsunami of cardiovascular disease in the long term. It’s critically important that young adults speak with their healthcare provider about whether ― and when ― they should undergo screening for high blood pressure, diabetes, and high cholesterol.’”

Working closely with healthcare providers is a key focus of HeartBeam’s technology. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required.

HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies.

For more information, visit the company’s website at www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php